Adamas Pharmaceuticals (NASDAQ:ADMS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Monday. They presently have a $40.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 243.35% from the company’s current price.
The analysts wrote, “Valuation methodology, risks and uncertainties. Our valuation ascribes a $1.15B valuation to GOCOVRI in PD $400M value for ADS-5102 based on a risk-adjusted net present value (rNPV) that employs a 15% discount rate, 30% effective tax rate and 30% cost of sales and marketing. We utilize a 60% probability of success for ADS-5102.””
Several other equities analysts have also weighed in on the stock. Mizuho lowered shares of Adamas Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $75.00 to $18.00 in a research report on Monday. ValuEngine lowered shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Cowen set a $30.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 1st. Leerink Swann restated an “outperform” rating on shares of Adamas Pharmaceuticals in a research report on Friday, October 19th. Finally, Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 8th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $35.11.
ADMS traded up $0.66 during trading on Monday, hitting $11.65. 5,923 shares of the company traded hands, compared to its average volume of 611,016. The firm has a market cap of $323.30 million, a P/E ratio of -2.80 and a beta of 1.53. The company has a debt-to-equity ratio of 1.01, a quick ratio of 8.74 and a current ratio of 8.95. Adamas Pharmaceuticals has a one year low of $10.58 and a one year high of $44.00.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.34) by $0.12. The company had revenue of $10.61 million during the quarter, compared to analyst estimates of $10.10 million. Adamas Pharmaceuticals had a negative net margin of 617.27% and a negative return on equity of 106.74%. Equities research analysts predict that Adamas Pharmaceuticals will post -5.37 earnings per share for the current fiscal year.
In other news, CFO Alfred G. Merriweather sold 1,665 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the transaction, the chief financial officer now directly owns 25,460 shares in the company, valued at $488,322.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 24.60% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of ADMS. FNY Investment Advisers LLC purchased a new position in shares of Adamas Pharmaceuticals in the second quarter worth $130,000. Metropolitan Life Insurance Co. NY raised its position in shares of Adamas Pharmaceuticals by 43.2% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,606 shares of the specialty pharmaceutical company’s stock worth $196,000 after purchasing an additional 2,293 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new position in shares of Adamas Pharmaceuticals in the 2nd quarter worth about $203,000. GSA Capital Partners LLP purchased a new position in shares of Adamas Pharmaceuticals in the 2nd quarter worth about $212,000. Finally, Voya Investment Management LLC purchased a new position in Adamas Pharmaceuticals in the 2nd quarter worth about $224,000. 95.65% of the stock is currently owned by hedge funds and other institutional investors.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Recommended Story: Float
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.